Clinical Research Directory

Inclusion Criteria: * Cohort 1 - Non-operable patients * Patients aged at least 18 years old and ≤ 70 years old; male or female. * AND available biopsy * AND Karnofsky index ≥ 50% at Screening * Cohort 2 - Elderly patients * Patients aged \> 70 years old; male or female * AND Balducci score I or II. For patients classified in Balducci II, only light Balducci II will be included, as defined by a Charlson score \<4 and a score of autonomy IADL = 4. In the oncogeriatric evaluation, symptoms related to brain cancer disease have not to be considered for this criterion. * Karnofsky score (KPS) of ≥ 70% at Screening * Regardless resection * MRI at maximum 48h00 after surgery if partial, subtotal or macroscopically complete or supra-total resection * For both cohorts * Histologically confirmed diagnosis of glioblastoma (GBM) (2016 OMS classification) (Louis et al., 2016). * Contrast enhancing disease on MRI within 14 days prior to screening. * Within 2 weeks of baseline visit, hematologic and renal functions as specified: Absolute neutrophil count ≥ 1500/mm3, platelets ≥ 100,000/mm3, Hgb ≥ 9.0g/dL, creatinine ≤ 1.7mg/dl, total bilirubin ≤ 1.5mg/dL, blood urea nitrogen (BUN) within 2 times the upper limit of normal, transaminases ≤ 4 times above the upper limits of the institutional norm. * Sexually active patients must use an acceptable method of contraception while receiving doses of study medication. * Females of childbearing potential must have a negative serum or urine pregnancy test at screening and have additional pregnancy tests during study. Exclusion Criteria: • For both cohorts * Any previous radiotherapy (RT) of the brain whatever the interval between previous brain RT and diagnoses of GBM) * Any previous treatment of the GBM (except surgery) such as chemotherapy (including Gliadel wafer or gliasite application), immunotherapy, therapy with a biologic agent, hormonal therapy or Carmustine implant for brain tumors or immunotherapy, including vaccination (whatever the interval between previous treatment and diagnoses of GBM). Glucocorticoid therapy is allowed. * Previous digestive disease with mis-absorption such as Crohn disease or chronic colitis * Ongoing diarrhea grade ≥ 2 in the NCI CTCAE V5.0 (whatever the cause) * Inclusion in another trial in the 30 previous days * Patient who cannot undergo MRI * Pregnant or lactating woman. * Serious concurrent infection or medical illness that would jeopardize the ability of the patient to receive study treatment with reasonable safety. * Patients with previous cancer (\< 5 years) except basocellular skin tumors and in situ cervix tumor * Patient has a known hypersensitivity to crocetins, L-TC or any of its excipients. * Contraindication of temozolomide as described in the Summary of product characteristics. * Patient who cannot understand French language. * Patient without French National Health insurance * Patient who cannot be reliable for follow-up * Patient under law protection